READOUT · 04 / DOSE CONTEXT
What the literature reports about dosing each GLOW constituent
No blend dose has ever been validated in a controlled human trial. These are constituent-level research figures, logged as context and nothing more.
There is no validated GLOW peptide dose
The first and most important fact about GLOW peptide dosing is the absence of one. The blend has never been dosed in a controlled human trial, so there is no validated or standardized dose for the GHK-Cu + BPC-157 + TB-500 combination. Everything below is constituent-level research data or a non-validated community and clinic convention, presented for context only.
No figure on this page is a recommendation. Each is reported as 'studied at X in [species or model]' so the research framing stays intact.
Constituent research figures, by leg
GHK-Cu: in-vitro fibroblast collagen synthesis was driven at 10^-12 to 10^-9 M; topical cosmetic formulations run approximately 0.05% to 2% (w/w) [1][2].
BPC-157: rodent tissue-repair studies used roughly 10 ng to 10 microg per rat per day, intraperitoneally; the Achilles study tested 10 microg, 10 ng or 10 pg per kg once daily [3]. A first-in-human IV safety pilot used 10 mg then 20 mg in two adults [10].
TB-500 / thymosin beta-4: rodent wound and stroke studies inform the leg; the human Phase 1 study gave full-length thymosin beta-4 IV at 42, 140, 420 and 1260 mg [5].
The commonly cited research-label blend ratio of 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial is a supplier labeling convention, not a clinically validated dose.
Half-life and routes studied
No pharmacokinetic data exist for the GLOW blend as a unit; combination kinetics have never been characterized. Among the constituents, BPC-157 has a short elimination half-life — under 30 minutes in rats and dogs — with linear kinetics and rapid breakdown to amino acids. The free GHK tripeptide is cleared rapidly by plasma peptidases, while topical GHK-Cu forms a dermal copper depot. Thymosin beta-4 showed dose-proportional kinetics, with half-life increasing with dose in its human Phase 1 study.
Routes studied are constituent-specific. GHK-Cu is predominantly topical, with rodent intraperitoneal and intranasal systemic studies [1]. BPC-157 was studied intraperitoneally and intramuscularly in animals and intravenously in the 2-subject human pilot [3][10]. Thymosin beta-4 was studied topically and intraperitoneally in animals and intravenously in humans [5]. Community 'GLOW' protocols describe subcutaneous injection of the reconstituted blend, but no peer-reviewed pharmacology supports subcutaneous blend dosing.
Reconstitution and stability, in research handling
Blend stability is formulation-specific and not characterized in the literature. In research handling, lyophilized BPC-157 and TB-500 are reconstituted with bacteriostatic water — sterile water containing 0.9% benzyl alcohol — and refrigerated.
The GHK-Cu complex is most stable near pH 5-6.5, and its blue-violet color indicates an intact Cu(II) complex; strong reducing agents and low-pH actives such as ascorbic acid can break it. Co-formulating a copper complex with two other peptides raises theoretical compatibility questions — copper redox chemistry, pH — that have not been studied for GLOW specifically. None of this is an instruction; it is the handling context the literature describes.